Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100117
Abstract: Background The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid… read more here.
Keywords: mcbs; clinical benefit; data analysis; implementation ... See more keywords
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100198
Abstract: Background Immune checkpoint inhibitors (ICIs) treatment is a breakthrough in managing metastatic solid tumours, but its use is associated with a high financial burden for public health care systems. Validated tools such as the European… read more here.
Keywords: clinical benefit; esmo; cost; metastatic solid ... See more keywords
Assessment of value for resource allocation in cancer care
Sign Up to like & getrecommendations! Published in 2017 at "Journal of cancer policy"
DOI: 10.1016/j.jcpo.2016.10.001
Abstract: Abstract There has been an increased interest in ways of measuring the value of new therapeutic options in oncology. An example of this in a European context is the ESMO Magnitude of Clinical Benefit Scale… read more here.
Keywords: cancer; assessment value; value; esmo mcbs ... See more keywords
ESMO-Magnitude of Clinical Benefit Scale version 1.1
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx310
Abstract: Background The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.0 (v1.0) was published in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit… read more here.
Keywords: clinical benefit; version; magnitude clinical; review ... See more keywords
Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz265.006
Abstract: Abstract Background Late lines of therapy (LL) offered to cancer patients (pts) are often characterized by scarce or doubtful clinical benefit and literature evidences about their use and their real impact on survival and quality… read more here.
Keywords: clinical benefit; care; benefit; esmo mcbs ... See more keywords
Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.6571
Abstract: 6571 Background: The American Society of Clinical Oncology Cancer Research Committee (ASCO-CRC), the ASCO Value Framework Net Health Benefit score version 2 (ASCO-VF), and the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version… read more here.
Keywords: esmo mcbs; approval; cancer; oncology ... See more keywords
Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1106961
Abstract: Background: Evidence of efficacy and safety of programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitors in oesophageal cancer (EC), gastric cancer (GC) and colorectal cancer (CRC) was inconsistent, obscuring their clinical… read more here.
Keywords: value assessment; cost; esmo mcbs; value ... See more keywords